WebDoctor Encyclopedia

Lung Non-small cell lung cancer

Pulmonary sarcomatoid carcinoma

Pulmonary sarcomatoid carcinoma is a rare, aggressive non-small cell lung cancer whose cells look like a sarcoma. It mostly affects older smokers, often responds poorly to chemotherapy, but frequently responds to immunotherapy or MET-targeted tablets.

Medically reviewed Last reviewed October 19, 2026

What is pulmonary sarcomatoid carcinoma?

Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive type of non-small cell lung cancer. “Sarcomatoid” means that some or all of the cancer cells look like those of a sarcoma, a cancer of connective tissue, even though the tumour began in the lining cells of the lung. Under the microscope, the cells are often spindle-shaped or very large and bizarre.

PSC makes up well under 1% of lung cancers. It mainly affects older men who smoke or used to smoke. The tumours are usually large when found, often grow into the chest wall, and can spread to unusual places such as the bowel.

Compared with other non-small cell lung cancers, PSC tends to respond poorly to chemotherapy. However, two discoveries have improved the outlook for some people. Many tumours carry high levels of PD-L1, which makes them more likely to respond to immunotherapy (Hong et al., 2025). Around one in eight carries a MET exon 14 skipping change, which can be treated with targeted tablets (Mazieres et al., 2023).

1. Key facts at a glance

Feature Details
Type of cancer Rare subtype of non-small cell lung cancer with sarcoma-like cells
How common Well under 1% of lung cancers
Typical age Usually over 60
Sex More common in men
Main risk factor Smoking
Typical presentation Large lung tumour, often with chest pain and cough
Common sites of spread Lymph nodes, brain, bone, adrenal glands, bowel
Key gene changes TP53, KRAS, MET exon 14 skipping, NF1
Main treatment Surgery for early disease; immunotherapy or targeted drugs for advanced disease
Outlook Poorer than other non-small cell lung cancers

2. Types of pulmonary sarcomatoid carcinoma

Subtype Description
Pleomorphic carcinoma Ordinary carcinoma mixed with spindle or giant cells; the most common subtype
Spindle cell carcinoma Made almost entirely of spindle-shaped cells
Giant cell carcinoma Made almost entirely of very large, bizarre cells
Carcinosarcoma Carcinoma mixed with true sarcoma elements such as cartilage, bone or muscle
Pulmonary blastoma Resembles fetal lung tissue; can occur in younger adults

The first three are closely related and are often grouped together. Carcinosarcoma and pulmonary blastoma are separate entities in the latest WHO classification but are still discussed under the sarcomatoid umbrella.

How PSC compares with other lung cancers

Feature Adenocarcinoma Squamous cell carcinoma Sarcomatoid carcinoma
Share of lung cancers The most common Common Well under 1%
Typical tumour Outer lung, variable size Central airways Large, outer lung, necrotic
Response to chemotherapy Moderate Moderate Poor
High PD-L1 Some Some Most
MET exon 14 skipping About 2-3% About 1% About 12%

3. Causes and risk factors

Risk factor Notes
Smoking Present in the large majority of patients
Older age Most patients are over 60
Male sex More men are affected
Asbestos or other workplace exposures General lung cancer risks
Radon gas A general lung cancer risk

Gene changes

Gene change Notes
TP53 Very common
KRAS Common; some carry KRAS G12C, which has targeted drugs
MET exon 14 skipping About 12% of sarcomatoid tumours, much higher than in other lung cancers
NF1, NF2 and NRAS More common than in adenocarcinoma
EGFR mutations and ALK fusions Rare

These findings come from a systematic review of MET exon 14 skipping (Mazieres et al., 2023) and a multicentre genomic study (Hong et al., 2025).

4. How does it look

On scans

Feature Description
Size Often large, over 5 cm
Location Frequently in the outer part of the lung, often the upper lobe
Centre Dead (necrotic) areas are common
Chest wall Growth into the ribs or chest wall in some cases
PET-CT Very bright, showing high activity

Under the microscope

Feature Description
Spindle cells Long, thin cells in bundles
Giant cells Huge cells with one or several bizarre nuclei
Carcinoma areas Gland-forming or squamous areas in pleomorphic carcinoma
Necrosis and bleeding Common

Special stains

Marker Typical result
Cytokeratins Positive, at least in part, confirming the tumour is a carcinoma
TTF-1 Sometimes positive
PD-L1 Often high (50% or more)
MET testing Done by DNA or RNA sequencing

Because PSC can look like a sarcoma, mesothelioma or melanoma, pathologists use stains to confirm the diagnosis. A small biopsy may miss the sarcomatoid part, so the final diagnosis is often made on the surgical specimen.

5. Symptoms

Common symptoms

  • A persistent cough
  • Chest pain, especially when the tumour grows into the chest wall
  • Breathlessness
  • Coughing up blood
  • Weight loss and loss of appetite
  • Tiredness
  • Fever or repeated chest infections

Symptoms of spread

Site Possible symptoms
Brain Headaches, weakness, seizures, confusion
Bone Bone pain, fractures
Bowel Abdominal pain, bleeding, anaemia, bowel obstruction
Adrenal glands Usually no symptoms
Lymph nodes Swelling above the collarbone

When to seek medical advice

See a doctor about a cough lasting more than three weeks, coughing up blood, chest pain or unexplained weight loss, especially if you smoke or used to smoke.

6. Diagnosis

Test Purpose
Chest X-ray Often the first test
CT of the chest and abdomen Shows the tumour and possible spread
PET-CT Detects spread to lymph nodes and other organs
Brain MRI Checks for brain spread
Bronchoscopy or CT-guided biopsy Obtains tissue
EBUS (endobronchial ultrasound) Samples lymph nodes in the chest
PD-L1 testing Guides immunotherapy
Molecular testing Looks for MET exon 14 skipping, KRAS G12C and other changes
Breathing tests Assess fitness for surgery

Why testing matters

Every person with advanced PSC should have their tumour tested for PD-L1 and for gene changes, ideally using a broad DNA and RNA sequencing panel. The results can be the difference between standard chemotherapy and a targeted tablet or immunotherapy. In a systematic review, MET inhibitors produced response rates of roughly 50-69% in MET exon 14-altered lung cancer as first treatment, compared with about 23-27% for chemotherapy (Mazieres et al., 2023). If there is not enough tissue, a liquid biopsy (blood test for tumour DNA) may help.

Staging

PSC is staged in the same way as other non-small cell lung cancers:

Stage Description
Stage I Small tumour, no lymph node spread
Stage II Larger tumour or spread to nearby lymph nodes
Stage III Spread to lymph nodes in the mediastinum (the central chest area between the lungs) or into nearby structures
Stage IV Spread to the other lung, the lining of the lung, or distant organs

7. Treatment

Treatment is planned by a lung cancer multidisciplinary team.

Early-stage disease

Treatment Notes
Surgery Lobectomy with lymph node removal is the main treatment
Adjuvant chemotherapy Linked with longer survival after surgery
Radiotherapy For people unable to have surgery, or after surgery in some cases
Perioperative immunotherapy Increasingly used in non-small cell lung cancer, including selected PSC

In a study of 1,640 patients in the US SEER database and 175 patients from a Shanghai hospital, chemotherapy after surgery was linked with longer survival, especially in people with larger tumours or lymph node spread (Sun et al., 2020).

What to expect around lung surgery

Stage What happens
Before Breathing tests, heart checks and advice to stop smoking
Operation Usually keyhole (VATS or robotic) lobectomy; open surgery for large tumours or chest wall involvement
Chest drain A tube removes air and fluid for a few days
Hospital stay Usually 3-7 days
Recovery Breathing exercises and walking; most people recover over 6-12 weeks
Chest wall resection Sometimes needed, with reconstruction, when ribs are involved

Advanced disease

Treatment When used
Immune checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) First choice for many patients, alone or with chemotherapy
MET inhibitors (capmatinib, tepotinib) For MET exon 14 skipping
KRAS G12C inhibitors (sotorasib, adagrasib) For KRAS G12C mutations
Chemotherapy Platinum-based; less effective than in other lung cancers
Radiotherapy For symptom relief and brain or bone spread

In a multicentre study of over 4,800 patients whose non-small cell lung cancer had already spread to distant sites, those with PSC did better on immunotherapy than on chemotherapy. Between 37% and 43% of PSC patients responded to immunotherapy, compared with 26-29% of those with adenocarcinoma. High PD-L1 levels appeared to explain this (Hong et al., 2025).

Side effects

Treatment Possible side effects
Lung surgery Pain, breathlessness, air leak, infection
Chemotherapy Tiredness, sickness, infection risk, nerve damage
Immunotherapy Inflammation of the lungs, bowel, liver, skin or hormone glands
MET inhibitors Swelling of the legs, nausea, kidney changes
Radiotherapy Tiredness, sore throat, skin changes, lung inflammation

8. Outlook (prognosis)

Measure Figure
Median survival (SEER, 1,640 patients) About 7 months
5-year survival (SEER) About 20%
5-year survival (Shanghai, 175 patients) About 25%

These figures come from Sun et al. (2020). Most patients in these cohorts were treated before immunotherapy and MET inhibitors became widely available, so current outcomes may be better.

Survival is linked with age, sex, tumour site, subtype, stage and treatment received. A prediction tool built on these factors performed better than stage alone (Wu et al., 2023). Early-stage disease removed with surgery has the best outlook.

Palliative and supportive care

Palliative care focuses on comfort and quality of life and can be given alongside active treatment. Teams help with breathlessness, pain, cough, tiredness and low mood. They also support families and help with planning for the future. Asking for palliative care early does not mean giving up on treatment.

9. Follow-up

Follow-up Purpose
CT scans every 3-6 months Detect recurrence
Brain MRI If symptoms suggest brain spread
Blood tests Monitor immunotherapy side effects, including thyroid and liver function
Clinic review Check symptoms, breathing and wellbeing

10. Living with pulmonary sarcomatoid carcinoma

  • Stop smoking: it improves treatment results, healing and breathing, and free support services can help
  • Stay active: pulmonary rehabilitation can improve breathing and fitness
  • Report new symptoms quickly, especially headaches, abdominal pain or breathlessness
  • Know the signs of immunotherapy side effects, such as diarrhoea, cough or rash
  • Eat well to maintain weight and strength, and ask for a dietitian referral if you are losing weight
  • Have your flu and pneumococcal vaccines, as chest infections can hit harder during treatment
  • Seek support from lung cancer charities, specialist nurses and palliative care teams

11. Frequently asked questions

Question Answer
Is PSC a sarcoma? No. It is a carcinoma whose cells look like sarcoma cells
Why is it hard to diagnose on biopsy? Small samples may miss the sarcomatoid part of the tumour
Will immunotherapy work? Many patients respond, particularly those with high PD-L1
Should my tumour have genetic tests? Yes; MET and KRAS changes can be treated with tablets
Is it caused by smoking? Smoking is the main risk factor, although some people who never smoked are affected
Does stopping smoking still help? Yes; it improves healing, breathing and response to treatment
Can PSC spread to the bowel? Yes; it is one of the lung cancers more likely to do so
Can it be cured? Sometimes, if found early and removed completely

12. Questions to ask your care team

  • What subtype of PSC do I have?
  • What is the stage?
  • Can the tumour be removed with surgery?
  • What is my PD-L1 level?
  • Has the tumour been tested for MET exon 14 skipping and KRAS G12C?
  • Would immunotherapy, chemotherapy or both be best for me?
  • Can I be referred to pulmonary rehabilitation or palliative care?
  • Am I eligible for a clinical trial?

Resources

  1. Hong, L. et al. (2025) ‘Distinct clinicogenomic features and immunotherapy associations in pulmonary sarcomatoid carcinoma: a multicenter retrospective study’, Journal of Thoracic Oncology, 20(12), pp. 1763-1777.
  2. Mazieres, J. et al. (2023) ‘MET exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes’, Clinical Lung Cancer, 24(6), pp. 483-497.
  3. Sun, L. et al. (2020) ‘Pulmonary sarcomatoid carcinoma: experience from SEER database and Shanghai Pulmonary Hospital’, Annals of Thoracic Surgery, 110(2), pp. 406-413.
  4. Wu, W. et al. (2023) ‘Survival analysis and nomogram for pulmonary sarcomatoid carcinoma: an SEER analysis and external validation’, BMJ Open, 13(10), e072260.
  5. National Cancer Institute (2026) Non-Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.